Newsletter – March 22, 2015

Newsletter – March 22, 2015


Recently, on December 15, 2014, the United States Court of Appeals for the Federal Circuit (CAFC) issued its opinion in Life Technologies Corporation v. Promega Corporation, Inc. regarding the boundaries of the term 'comprising'. In patent practice the use of the term “comprising” in a claim signifies the elements or components specified plus anything else; this is referred to as “open claim language”.

The court held that claims in four US Patents ('the Promega patents') directed to methods and kits for simultaneous analysis of DNA regions comprising 3 specific repeating sequence regions are invalid for lack of enablement. According to the decision, “the surprising and unpredictable nature” of the biotechnology field was an important factor, as the quality of analysis upon inclusion of additional repeating sequence regions to the analytic protocol would result in a potentially unreliable outcome.


Newsletter – November 20, 2013

Webb & Co are branching out

We are happy to announce that we have now opened a new branch in Herzliya Pituach.

The Herzliya office is located at Ackerstein Towers, 11 HaMenofim St., Building B.

The phone numbers and mailing address remain the same.

We look forward to continue working with you and collaborating with you in one of our offices.

The Webb & Co team

Newsletter – October 1, 2013

From IP to NP (Net Profit)

Dear all,

We are pleased to inform you that the first international conference “From IP to NP (Net Profit)” organized by the AIPPI (International Association for the Protection of Intellectual Property), will be held at the Tel-Aviv Dan Panorama on November 10 – 11, 2013.

Webb & Co. is proud to be part of the program. The conference is intended for entrepreneurs, IP managers and professionals, scientists and any other party interested in intellectual property.

We will be glad to see you there. Please find the link to the conference schedule and registration:

The Webb & Co. team


Newsletter – June 17, 2013

Newsletter – June 17, 2013



Last week the U.S. Supreme Court issued its opinion in the Association for Molecular Pathology v. Myriad Genetics, Inc. (2013). The court held that synthetically produced genetic material is a patentable subject matter, however, naturally occurring DNA isolated from the human body is not. The court found that a naturally occurring DNA segment is a product of nature and is not patent eligible merely because it has been isolated, while complementary DNA (cDNA) is patent eligible because it is not naturally occurring.


Newsletter – February 19, 2013

Newsletter – February 19, 2013

United States Patents First to File System Effective as of March 16, 2013

On September 16, 2011, President Obama signed into law the Leahy-Smith America Invents Act (“AIA”). While many provisions of the AIA became effective upon enactment, the key feature regarding a first-inventor-to-file system will become effective on March 16, 2013.